

Indoco's API facility at Patalganga completes US FDA inspection with zero observations

Our Bureau, Bengaluru

Friday, September 19, 2025, 16:25 Hrs [IST]

Indoco Remedies, a fully integrated, research-oriented pharmaceutical company, has announced that the United States Food and Drug Administration (FDA) successfully completed inspection of its active pharmaceutical ingredients (API) manufacturing facility at Patalganga. The inspection concluded with zero form 483 observations, reflecting the company's commitment to the highest standards of quality, regulatory compliance and operational excellence.

“This successful US FDA inspection is a testament to the strong quality culture and compliance in every process and every product. We remain committed to strengthening our systems to deliver safe and efficacious medicines across the globe,” said Aditi Panandikar, managing director, Indoco Remedies Limited.

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The company's turnover is US\$ 180 million with a human capital of over 6,000 employees, including over 400 skilled scientists and field staff who are the strength of the organization.